Risperdal Consta is the long-acting injectable form of risperidone. Approved by the FDA in 2003, it was the first LAI to be made from an atypical (second-generation) antipsychotic — a significant moment in psychiatry, given that depots had previously been only typical antipsychotics like haloperidol decanoate and fluphenazine decanoate. Risperdal Consta is given as an intramuscular injection every 2 weeks.
Risperdal Consta is the bi-weekly intramuscular injectable form of risperidone — historically important as the first atypical LAI, with a 3-week oral overlap requirement and a relatively short dosing interval compared to newer options.
How the depot works
Risperdal Consta uses a microsphere technology: risperidone is encapsulated in tiny biodegradable polymer beads suspended in an aqueous medium. After injection into the deltoid or gluteal muscle, the polymer slowly hydrolyses, releasing risperidone gradually over about 4 to 6 weeks — but with the bulk of release happening between weeks 3 and 6.
Because of this delayed-release pattern, oral risperidone must be continued for the first 3 weeks after the first Consta injection. This is the longest oral overlap requirement of any major LAI on the market.
Dosing
Risperdal Consta is dosed every 2 weeks, with standard dose strengths. The right dose for any individual depends on their oral risperidone dose, response, and tolerance.
The oral overlap requirement
The 3-week oral overlap is the main practical difference between Risperdal Consta and most newer LAIs. Specifically:
- Patient must tolerate oral risperidone first (to confirm no allergy or severe intolerance)
- After the first Consta injection, oral risperidone continues for 3 weeks
- After 3 weeks, oral can be stopped — depot release covers symptom control from then on
For patients who struggle with daily oral medication, this 3-week oral period is a significant limitation. Newer LAIs (Invega Sustenna, Perseris) have eliminated or shortened this requirement.
Missed-dose protocols
Because Consta releases risperidone unevenly across the 2-week dosing interval, missed doses can have a meaningful impact on blood levels. The FDA labelling specifies catch-up protocols depending on how many days have passed since the last injection. Specific catch-up plans belong to the prescriber.
Call the clinic — Consta's release pattern means missed doses can quickly produce gaps in coverage. The catch-up protocol depends on timing.
Side effects
The side effect profile of Risperdal Consta mirrors oral risperidone, plus injection-related effects:
- Hyperprolactinaemia — risperidone is one of the strongest prolactin-elevating antipsychotics. Can cause irregular periods, breast tenderness or discharge, sexual dysfunction.
- Weight gain and metabolic changes — moderate, less than olanzapine but real
- EPS — moderate, particularly akathisia
- Sedation — usually mild to moderate
- Orthostatic hypotension — modest
- Tardive dyskinesia with long-term use
See our deeper guides on risperidone side effects and extrapyramidal symptoms.
Injection-site reactions
- Pain at the injection site for 1 to 3 days after the shot
- Swelling, mild bruising, or a small lump (usually resolves)
- Rare persistent nodules
Who Risperdal Consta fits
- Patients who have done well on oral risperidone and prefer an injectable form
- Settings where Consta is the only available risperidone LAI
- Patients used to bi-weekly visits and who value the more frequent contact
Who might want to consider alternatives
- Patients who struggle with daily oral medication — the 3-week oral overlap is a significant burden
- Patients who want fewer injections per year — monthly LAIs (Invega Sustenna, Perseris) require half as many trips to the clinic
- Patients with hyperprolactinaemia symptoms — newer agents like aripiprazole-based LAIs may be a better fit
How it compares to other risperidone-family LAIs
The risperidone family of LAIs has expanded in recent years:
- Invega Sustenna — monthly intramuscular paliperidone (the active metabolite of risperidone). No long oral overlap.
- Invega Trinza — every-3-month paliperidone
- Perseris — monthly subcutaneous risperidone
- Uzedy and Rykindo — newer monthly injectable risperidone formulations introduced after Consta
Most clinicians starting an LAI today choose one of the newer agents for the simpler initiation and longer dosing intervals. Risperdal Consta remains a reasonable choice for patients already stable on it or in settings where the alternatives are unavailable.
The bigger picture
Risperdal Consta opened the door to a generation of atypical LAIs and showed that long-acting depot dosing wasn't only for first-generation antipsychotics. Even as newer formulations have largely overtaken it, its role in psychiatric history is genuine — and for patients doing well on it, there is rarely a reason to switch.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.